Canaccord Genuity Maintains Buy on Pacific Biosciences, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Pacific Biosciences (NASDAQ:PACB) and raises the price target from $14 to $17.
June 05, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains Buy rating on Pacific Biosciences and raises price target from $14 to $17.
The raised price target by Canaccord Genuity analyst Kyle Mikson indicates a positive outlook for Pacific Biosciences. This could lead to increased investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100